Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa

AIDS

Volumn 28, Issue SUPPL. 1, 2014, Pages

  Martin, Natasha K ^a,b   Devine, Angela ^b   Eaton, Jeffrey W ^c   Miners, Alec ^b   Hallett, Timothy B ^c   Foster, Graham R ^d   Dore, Gregory J ^e   Easterbrook, Philippa J ^f   Legood, Rosa ^b   Vickerman, Peter ^a,b  

^a University of Bristol Canynge Hall   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antiretroviral therapy; coinfection; hepatitis B virus; hepatitis C virus; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; EPIDEMIC; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIVER CIRRHOSIS; MIXED INFECTION; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SOUTH AFRICA; VERTICAL TRANSMISSION; VIREMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; SECONDARY PREVENTION; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 84893311774     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000084     Document Type: Article

References (83)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-S9.
2. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: Advances and challenges. Gut 2012; 61:i47-i58.
3. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001; 33:562-569.
4. Thein H-H, Yi Q, Dore G, Krahn M. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A metaanalysis. AIDS 2008; 22:1979-1991.
5. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
6. Chen T-Y, Ding EL, Seage GR, Kim AY. Meta-analysis: Increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49:1605-1615.
7. World Hepatitis Alliance. Viral hepatitis: Global policy report. 2010. http://www.worldhepatitisalliance.org/Policy/2010Policy Report.aspx.
8. Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. J Am Med Assoc 2012; 308:370-378.
9. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013; 381:468-475.
10. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 51:98-107.
11. Liaw Y, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology 2011; 54:91-100.
12. Matthews G, Cooper DA, Dore GJ. Improvements in parameters of end-stage liver disease in patients with HIV/HBVrelated cirrhosis treated with tenofovir. Antivir Ther 2007; 12:119-122.
13. WHO. Consolidated ARV guidelines 2013 web annexes. 2013. http://www.who.int/hiv/pub/guidelines/arv2013/annexes/en/.
14. WHO. Global update on HIV treatment 2013: Results, impact and opportunities. 2013. http://apps.who.int/iris/bitstream/10665/85326/1/ 9789241505734-eng.pdf.
15. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. Geneva: WHO; 2010. http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf.
16. Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretorival therapy. N Engl J Med 2011; 365:493-505.
17. Sterne J, May M, Costagliola D, De Wolf F, Phillips A, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
18. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727- eng.pdf.
19. UNAIDS. UNAIDS report on the global AIDS epidemic. Geneva; 2012. http://www.unaids.org/en/media/unaids/con tentassets/documents/epidemiology/ 2012/gr2012/20121120-UNAIDS-Global-Report-2012-en.pdf.
20. Gededzha M, Mphahlele M, Lukhwareni A, Selabe S. Should routine serological screening for HCV be mandatory in HIV/AIDS patients enrolling for HAART in South Africa. South Afr Med J 2010; 100:814-815.
21. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore G. HIV and hepatitis C co-infection within CAESAR study. HIV Med 2004; 5:174-179.
22. Cherry CL, Affandi JS, Brew BJ, Creighton J, Djauzi S, Hooker DJ, et al. Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Neurology 2010; 74:1538-1542.
23. Lodenyo H, Schoub B, Ally R, Kairu S, Segal I. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. E Afr Med J 2000; 77:13-15.
24. Barth RE, Huijgen Q, Tempelman HA, Mudrikova T, Wensing AMJ, Hoepelman AIM. Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa. J Med Virol 2011; 83:929-934.
25. Parboosing R, Paruk I, Lalloo U. Hepatitis C virus seropositivity in a South African cohort of HIV co-infected, ARV nave patients is associated with renal insufficiency and increased mortality. J Med Virol 2008; 80:1530-1536.
26. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002; 2:293-302.
27. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol 2009; 81:406-412.
28. Burnett RJ, Ngobeni JM, François G, Hoosen AA, Leroux-Roels G, Meheus A, et al. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. Int J STD AIDS 2007; 18:152-156.
29. Hoffman C, Charalambous S, Thio CL, Martin D, Pemba L, Fielding K, et al. Hepatotoxicity in an African antiretroviral therapy cohort: The effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308.
30. Firnhaber C, Reyneke A, Schulze D, Malope B, Maskew M, MacPhail P, et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J 2008; 98:541-544.
31. Chang M-H. Chronic hepatitis virus infection in children. J Gastroenterol Hepatol 1998; 13:541-548.
32. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7:402-409.
33. Johnson LF, Mossong J, Dorrington R, Schomaker M, Hoffman C, Keiser O, et al. Life expectancies of HIV-positive adults receiving antiretroviral treatment in South Africa. ASSA Convention 2012; 2012:93-118.
34. Johansson K, Robberstad B, Norheim O. Further benefits by early start of HIV treatment in low income countries: Survival estimates of early versus deferred antiretroviral therapy. AIDS Res Ther 2010; 7:3.
35. Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: Evidence from a large cohort in Uganda. AIDS 2011; 25:851-855.
36. Brinkhof M, Boulle A, Weigel R, Messou E, Mathers C, Orell C, et al. Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: Comparison with HIV-unrelated mortality. PLoS Med 2009; 6:e1000066.
37. Mahy M, Lewden C, Brinkhof MWG, Dabis F, Tassie J-M, Souteyrand Y, et al. Derivation of parameters used in spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect 2010; 86:ii28-ii34.
38. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis c infection in an evolving patient population. J Am Med Assoc 2003; 290:228-237.
39. Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stagespecific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology 2008; 48:418-431.
40. Pineda JA, Romero-Gómez M, D́az-Garća F, Girón-González JA, Montero JL, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with hepatitis C virusrelated decompensated cirrhosis. Hepatology 2005; 41:779-789.
41. Klein M, Lalonde R, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretoriviral therapy. J Acquir Immune Defic Syndr 2003; 33:365-372.
42. Melvin D, Lee J, Belsey E, Arnold J, Murphy R. The impact of coinfection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 2000; 14:463-465.
43. Sulkowski M, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. J Am Med Assoc 2002; 288:199-206.
44. Law W, Dauncombe C, Mahanontharit A. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169-1177.
45. Chung RT, Evans S, Yang Y, Theodore D, Valdez H, Clark R, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16:1915-1923.
46. Di Martino V, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812-1822.
47. Gilson R, Hawkins A, Beecham M, Ross E, Waite J, Briggs M, et al. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 1997; 11:597-606.
48. Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 2013; 56:e87-e94.
49. De Vries-Sluijs TEMS, Reijnders JGP,Hansen BE, ZaaijerHL, Prins JM, PasSD, et al. Long-termtherapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139:1934-1941.
50. Nikolopoulo GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: A cohort study and meta-analysis. Clin Infect Dis 2009; 48:1763-1771.
51. Konopnicki D, Mocroft A, De Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
52. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012; 380:2129-2143.
53. WHO. Making choices in health: WHO guide to cost-effectiveness analysis. In Tan-Torres Edejer T, Baltussen R, Adam T, et al., editors. Geneva; 2003. http://www.who.int/choice/pub lications/p-2003-generalised-cea.pdf.
54. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
55. Braitstein P, Zala C, Yip B, Brinkhof MWG, Moore D, Hogg RS, et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 2006; 193:259-268.
56. De Luca A, Bugarini R, Lepri A, Puoti M, Girardi E, Antinori A. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-2132.
57. ShengW-H,ChenM-Y,Hsieh S-M,Hsiao C-F,Wang J-T,Hung CC, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004; 38:1471-1477.
58. Hershow RC, ODriscoll PT, Handelsman E, Pitt J, Hillyer G, Serchuck L, et al. Hepatitis C virus coinfection and HIV load, CD4R cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 2005; 40:859-867.
59. National Department of Health South Africa and South African National AIDS Council. PMTCT (Prevention of Mother-to-Child Transmission) clinical guidelines. Republic of South Africa Department of Health; 2010. http://www.fidssa.co.za/images/PMTCT-Guidelines.pdf.
60. Republic of South Africa Department of Health. The South African Antiretroviral Treatment Guidelines 2013; 1 April 2013. http://www.doh.gov.za/ docs/policy/2013/ART-Treatment-Guidelines-Final-25March2013.pdf
61. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: Systematic review and metaanalysis. Br Med J 2006; 332:328-336.
62. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: A systematic review and meta-analysis. Obstet Gynecol 2010; 116:147-159.
63. Polis C, Shah S, Johnson K, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: A meta-analysis. Clin Infect Dis 2007; 44:1123-1131.
64. Bower WA, Culver DH, Castor D, Wu Y, James VN, Zheng H, et al.Changes in hepatitisCvirus (HCV) viral load andinterferon-[alpha] levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. JAIDS 2006; 42:293-297.
65. Liu X, He N, Fu Z, Duan S, Gao M, Zhang Z. Plasma hepatitis C virus viral load among hepatitis C virus mono-infected and HCV/HIV co-infected individuals in Yunnan Province, China. Hepat Mon 2012; 12:453-459.
66. Ragni M, Bontempo F. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180:2027-2029.
67. European Paediatric Hepatitis C Virus Network. A significant sex-but not elective cesarean section-effect on mother-tochild transmission of hepatitis C virus infection. J Infect Dis 2005; 192:1872-1879.
68. Campos N, Salomon J, Servoss J, Nunes D, Samet J, Freedberg K, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007; 120:272-279.
69. Hornberger J, Torriani FJ, Dieterich DT, Brau N, Sulkowski MS, Torres MR, et al. Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol 2006; 36:283-291.
70. Kuehne F, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: Clinical benefits and cost-effectiveness. Arch Intern Med 2002; 162:2545-2556.
71. Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, HarrisP,etal.Adefovirdipivoxilandpegylatedinterferonalphafor thetreatmentofchronichepatitisB:anupdatedsystematicreview andeconomicevaluation. HealthTechnolAssess2009;13:1-195.
72. Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in themanagement of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat 2007; 14:751-766.
73. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value In Health 2010; 13:922-933.
74. Le Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Pathogenesis of hepatitis C during pregnancy and childhood. Viruses 2012; 4:3531-3550.
75. Van Der Helm J, Geskus R, Sabin C, Meyer L, del Amo J, Chene G, et al. Effect of HCV infection on cause-specific mortality following HIV seroconversion before and after 1997. Gastroenterology 2012; 144:751-760.
76. Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, et al. Prognostic indicators for aids and infectious disease death in hiv-infected injection drug users: Plasma viral load and CD4R cell count. J Am Med Assoc 1998; 279:35-40.
77. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. J Am Med Assoc 1998; 280:544-546.
78. Nelson PK, Mathers BM, Cowle B, Hagan H, Des Jarlais DC, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011; 378:571-583.
79. Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users An ecological analysis. Addiction 2009; 105:311-318.
80. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. Lancet 2010; 376:285-301.
81. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: The past, present, and future. Lancet 2014; 376:268-284.
82. Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust 2012; 196:629-632.
83. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58:1598-1609.